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INTRODUCTION
Several provocative tests have been designed to establish predictive
factors for glaucoma(1-3). However, none of them have proved to be of clinical
value.
Ibopamine (N-methyldopamine 3,4 diisobutyric ester) eye drops are
hydrolyzed to epinine, an analogue of dopamine. Epinine binds to α-adre-
nergic and D-1 dopaminergic receptors. The adrenergic binding causes a
non-cycloplegic mydriasis, while the D-1 dopaminergic action causes an
increase in aqueous humor production(4-8). Because it increases aqueous
humour production, ibopamine eyedrops have been successfully used to
treat post-trabeculectomy hypotony(9-10). Since many glaucomas may have
an impaired outflow system, glaucoma subjects usually have a greater rise
in intraocular pressure compared to normal subjects(7,11-14).
However, despite presumable minor systemic effects of ibopamine eye
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Purpose: To compare intraocular pressure (IOP) rise in normal individuals
and primary open-angle glaucoma patients and the safety and efficacy of
ibopamine eye drops in different concentrations as a provocative test for
glaucoma.Methods:Glaucoma patients underwent (same eye) the ibopamine
provocative test with two concentrations, 1% and 2%, in a random
sequence at least 3 weeks apart, but not more than 3 months. The normal
individuals were randomly submitted to one of the concentrations of
ibopamine (1% and 2%). The test was considered positive if there was an
IOP rise greater than 3 or 4 mmHg at 30 or 45 minutes to test which subset
of the test has the best sensitivity (Se)/specificity (Sp). Results: There was
no statistically significant difference in any of the IOP measurements,
comparing 1% with 2% ibopamine. The IOP was significantly higher at 30
and 45 minutes with both concentrations (p<0.001). The best sensitivity/
specificity ratio was achieved with the cutoff point set as greater than 3
mmHg at 45 minutes with 2% ibopamine (area under the ROC curve: 0.864,
Se: 84.6%; Sp:73.3%). All patients described a slight burning after
ibopamine’s instillation. Conclusion: 2% ibopamine is recommended as a
provocative test for glaucoma. Because both concentrations have similar
ability to rise IOP, 1% ibopamine may be used to treat ocular hypotony.
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drops when used as a provocative test (only 2 drops), ibopa-
mine is a dopaminergic analogue used in cardiac diseases with
some described adverse effects(15-17). Patients using ibopami-
ne to treat ocular hypotony would be at greater risk of adverse
events, since they would be using ibopamine eyedrops 3 to 4
times/day(10). Thus, ibopamine eye drops with lower concen-
tration and similar efficacy are desirable.
All studies with ibopamine as a provocative test for glau-
coma have used the 2% eye drops(7,11-14). However, the ibopa-
mine is also commercially available at 1%. The purpose of this
study is to compare intraocular pressure (IOP) rise in normal
individuals and in primary open-angle glaucoma patients and
the safety and efficacy of the ibopamine eye drops in different
concentrations as a provocative test for glaucoma.
METHODS
This is a prospective comparative study including glauco-
ma patients from the Federal University of Goiás, Glaucoma
Service. Normal subjects were recruited from volunteers of the
medical staff, university members, family and friends of pa-
tients. Only one eye per subject was randomly selected if both
were eligible. An informed and written consent was obtained
for both groups. This study followed the tenets of the Decla-
ration of Helsinki and was approved by the Ethics Committee
of the Federal University of Goiás.
The inclusion criteria for the glaucomatous group were:
primary open-angle glaucoma: IOP ≥21 mmHg at least on two
occasions, as measured by a calibrated Goldmann tonometer;
gonioscopy showing an open angle; typical optic disc neuro-
pathy, that is, localized or generalized narrowing of the neuro-
retinal rim, disc hemorrhage, or cup/disc asymmetry >0.2 and
at least two reliable and recent (at least 6 months) SITA Stan-
dard Humphrey 24-2 abnormal visual fields(18).
Normal subjects were included after a comprehensive oph-
thalmic examination, including Goldmann applanation tonometry
(IOP <21 mmHg), an absence of glaucomatous optic disc (as
described above), gonioscopy showing an open angle and a
normal and reliable SITA Standard 24-2 perimetric examination(18).
Exclusion criteria included narrow angles, secondary glau-
coma, ocular hypertension (IOP >21 mmHg with normal optic
disc and perimetric examination), glaucoma suspects (based on
the optic disc, but with IOP <21 mmHg and no corresponding
field damage) or any significant change on slit lamp examination
that could interfere with the perimetric examination (i.e: macular
degeneration) or with the tonometry (i.e: corneal scars). We
also excluded patients who underwent refractive surgery, using
prostaglandin analogues(11), recent history (6 months) of ocular
inflammation, functional anti-glaucomatous surgery (trabecu-
lectomy, tube shunts), inability to perform any of the examina-
tions or refusal to participate in the study.
The eligible glaucoma patients were submitted (same eye) to
the ibopamine provocative test at 2 concentrations, 1% and 2%,
in a random sequence at least 3 weeks apart, but not more than
3 months. The normal individuals were randomly submitted to
one of the concentrations of the ibopamine (1% or 2%). All
participants followed a standardized sequence: baseline IOP
measurement around 9:00 o’clock AM, instillation of 2 ibopami-
ne eyedrops, 5 minutes apart, followed by IOP measurement 30
and 45 minutes after the second drop. Mydriasis was conside-
red as total (> 6 mm) or not (< 6 mm) in all patients as measured
by a horizontal slit in the biomicroscopy examination.
The IOP considered was the mean of two consecutive
measurements, always using the same calibrated tonometer by
the same masked examiner (a second person read the IOP). If
the difference between the first and the second measurements
was greater than 2 mmHg, a third measurement was made, with
the most discrepant value discarded.
Statistical analysis was done with the SPSS software (SPSS
Inc, Chicago, IL,), version 11.5. The Komogorov-Smirnov test
was used to test the normality of our distribution. The paired t
test was used to compare the IOP before and after ibopamine
instillation in both concentrations, and between them. The IOP
in the normal individuals was compared with the independent
student’s t test. Considering the alpha error as 0.05, power of
80%, standard deviation within groups as 1, and the difference
of means to be detected as 1, the necessary sample size to
detect significant differences between groups was set as 10 for
the paired tests and 17 for the unpaired comparison. The ibopa-
mine test was considered positive when the IOP increase excee-
ded 3 (cutoff number 1) or 4 mmHg (cutoff number 2) at 30
minutes (timepoint number 1) or 45 minutes (timepoint number
2) sensitivity and specificity of the test were calculated for each
subset of the test and ROC curves created to find the best area
under the curve and cutoff point in the diagnosis of glaucoma
for each ibopamine concentration at 30 and 45 minutes. Any
systemic adverse event noticed by the patients was considered
as ibopamine’s side effect.
RESULTS
Thirteen glaucoma patients were included (two women).
The mean age was 64.3±9.7 years old. The mean Mean Devia-
tion (MD) was -5.1±1.7 dB (from -2.59 dB to -9.33 dB), and the
mean Pattern Standard Deviation was 5.2±2.1 dB (from 1.74 to
8.50). In the normal group, 15 subjects were submitted to 2%
ibopamine test (mean age: 51.8±14.4 years old, 11 women and 2
men) and in 13 individuals 1% ibopamine was instilled (mean
age: 55.1±8.5 years old, p=0.4; 7 women and 6 men). Complete
mydriasis (>6 mm) was achieved in all individuals with both
concentrations.
IOP distribution in the glaucoma group is illustrated in table 1.
There was no statistically significant difference in any of the
measurements, comparing the ibopamine test at 1% with ibopami-
ne test at 2% (Table 1). The IOP was significantly higher at 30 and
45 minutes with both concentrations (p<0.001 for all tests). IOP in
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the normal individuals is shown in table 2. IOP was significantly
higher in the normal individuals at 30 minutes (p=0.003 with 2%
ibopamine and p=0.001 with 1% ibopamine) and at 45 minutes
with 2% ibopamine (p=0.007). IOP rise was borderline with 1%
ibopamine at 45 minutes (p=0.05).
The sensitivity and specificity for all analyzed cutoffs and
timepoints are displayed in table 3. The area under the ROC
curve was 0.781 (95% confidence interval, CI: 0.598; 0.964) and
0.861 (95% CI: 0.717; 1.004) (Figure 1) for the 1% Ibopamine
provocative test at 30 and 45 minutes, respectively. The 2%
ibopamine provocative test achieved an area under the ROC
curve of 0.736 (95% CI: 0.544; 0.928) at 30 minutes and an area
under the ROC curve of 0.864 (95% CI: 0.722; 1.006) at 45
minutes (Figure 2). The best cutoff (IOP rise) in all timepoints for
all ibopamine concentrations was greater than 3 mmHg. No sub-
jective systemic effect was noticed in the whole study. All pa-
tients described a slight burning after ibopamine’s instillation.
DISCUSSION
In developed countries, fewer than 50% of those with
glaucoma are aware of their disease. In the developing world,
the rate of known disease is even lower(19). Screening metho-
ds for glaucoma, including an accurate and easy to perform
provocative test would decrease the number of impaired peo-
ple due to glaucoma and also reduce the direct and indirect
costs of the disease(20).
Ibopamine has been used as a provocative test for glauco-
ma in the past few years with good sensitivity and specificity in
the diagnosis of glaucoma(11-12,14). Additionally, excluding the
prostaglandin analogues, the use of anti-glaucomatous drugs
do not alter the test’s performance(11). Thus, we only eliminated
from our analysis patients using this class of drugs.
The glaucomatous population had, as an average, initial
visual field damage (MD: -5.1±1.7 dB). In a screening program,
Table 1. Intraocular pressure distribution in the glaucoma group
Intraocular pressure (mmHg) Test Mean Standard deviation p*
Baseline 2% ibopamine 18.07 4.34 1.00
1% ibopamine 18.07 2.21
After 30 minutes 2% ibopamine 22.38 4.36 0.80
1% ibopamine 22.23 3.32
After 45 minutes 2% ibopamine 23.76 3.85 0.30
1% ibopamine 23.00 3.55
IOP rise after 30 minutes 2% ibopamine 04.30 3.03 0.80
1% ibopamine 04.15 2.30
IOP rise after 45 minutes 2% ibopamine 05.69 2.75 0.30
1% ibopamine 04.92 2.49
* Paired t test
Table 2. Intraocular pressure distribution in the normal group
Intraocular pressure (mmHg) Test Mean Standard deviation p*
Baseline 2% ibopamine 15.46 2.06 0.2
1% ibopamine 14.00 3.35
After 30 minutes 2% ibopamine 17.38 2.21 0.2
1% ibopamine 15.86 4.24
After 45 minutes 2% ibopamine 16.61 2.66 0.5
1% ibopamine 15.66 4.46
IOP rise after 30 minutes 2% ibopamine 01.92 1.65 0.9
1% ibopamine 01.86 2.03
IOP rise after 45 minutes 2% ibopamine 01.15 1.95 0.5
1% ibopamine 01.66 2.02
* Independent Student’s t test
Table 3. Sensitivity and specificity of the ibopamine provocative test
Timepoint Cutoff 1% Ibopamine 2% Ibopamine
Sensitivity Specificity Sensitivity Specificity
After 30 minutes >3 mmHg 61.5% 84.6% 69.2% 73.3%
>4 mmHg 46.1% 92.3% 38.4% 93.3%
After 45 minutes >3 mmHg 69.2% 100.0% 84.6% 73.3%
>4 mmHg 61.5% 100.0% 61.5% 86.6%
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suggested the best sensitivity/specificity ratio with 1% ibopa-
mine at 45 minutes (area under the ROC curve: 0.861, Figure 1),
similar to the 2% ibopamine at the same timepoint, especially
due to a high specificity (100%), with reasonable sensitivity
(69.2%) with ibopamine at the lower concentrations. However,
the ideal for a provocative test for glaucoma would be an easy
protocol with high sensitivity (to diagnose people that really
have glaucoma), but with acceptable specificity (not to treat
normal individuals as glaucoma patients). Moreover, after a
screening process, follow-up visits may rule out normal indivi-
duals, but we could miss the chance to diagnose and treat a new
glaucoma case. In this way, we believe the 2% ibopamine
should be the choice for a provocative test for glaucoma, with a
cutoff point set greater than 3 mmHg at 45 minutes in order to
achieve the best sensitivity (84.6%) and acceptable specificity
(73.3%). Furthermore, in a recent study, we have found that the
2% ibopamine provocative test was correlated with the IOP
peak in the diurnal tension curve, better at 45 minutes than at 30
minutes (unpublished data).
On the other hand, both ibopamine concentrations have
reliably increased IOP in normal individuals and glaucoma pa-
tients, with no noticeable difference between the concentra-
tions (Tables 1 and 2). Consequently, it is possible to use 1%
ibopamine to treat post-surgery(9,10) or post-uveitis(22) ocular
hypotony with the same efficacy of 2% ibopamine. Despite no
adverse effect in the study, all individuals received a small dose
(2 drops). However, the probability of adverse systemic events
with the chronic use of ibopamine, such as long-term hyperten-
sion, is higher, and demands its use in lower concentrations.
CONCLUSION
The ibopamine provocative test is safe and has good sen-
sitivity and specificity, with both concentrations of the drug
(1% and 2%). However, due to a higher sensitivity, the 2%
Ibopamine is recommended. Because both concentrations ha-
ve similar ability to raise the IOP, 1% ibopamine may be used
to treat ocular hypotony.
Figure 1 - ROC curves for the 1% ibopamine provocative test Figure 2 - ROC curves for the 2% ibopamine provocative test
we need to identify not only those who are at risk of blind-
ness, but also initial glaucoma, in order to prevent eventual
visual impairment. Furthermore, IOP rise after the ibopamine
test is usually higher in advanced glaucoma(21), presumably
due to a more severe impairment of the outflow system, with
consequent better sensitivity/specificity. Therefore, we used
the same glaucoma population in order to avoid an inclusion
bias, and consequently a flawed conclusion due only to a
difference in the glaucoma severity in our study groups. Ho-
wever, normal individuals are expected to have a normal out-
flow system. Thus, we decided to use two normal populations
(1% ibopamine and 2% ibopamine) to avoid any further incon-
venience, though with no inclusion bias.
We checked the IOP at two different timepoints (30 and 45
minutes) with two different cutoffs (3 and 4 mmHg) in order to
achieve the optimum performance of the test, since studies have
used different definitions to interpret the ibopamine provocative
test(7,11,14). Recently, we found a sensitivity of 87% and a specifi-
city of 95% with the provocative test in the diagnosis of glauco-
ma with the cutoff set as greater than 4 mmHg at 30 minutes(11). De
Gregorio et al.(14) have achieved better results, a sensitivity of
92% and a specificity of 100% in the diagnosis of primary open-
angle glaucoma with IOP rise >3 mmHg as the cutoff at 45 mi-
nutes. In the present study, the best sensitivity/specificity ratio
was achieved with the cutoff point set as greater than
3 mmHg at 45 minutes with 2% ibopamine (area under the ROC
curve: 0.864, Figure 2). We believe this difference was observed
because in the past study, our population basically consisted of
moderated and advanced glaucoma (63%), and therefore the
likelihood of IOP rise is greater, even at a shorter time. Additio-
nally, in the last protocol, we did not measure IOP at 45 minutes,
but only at 30, 60 and 180 minutes, since we were interested in
evaluating the IOP behavior after ibopamine instillation during
the day, and not only the test’s performance(11).
We believe this is the first study with 1% ibopamine. Despi-
te small systemic absorption of any ophthalmic solution, ibopa-
mine is a dopaminergic analogue, and consequently the risks
are probably directly related to its concentration. Our results
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RESUMO
Objetivo: Comparar a tolerabilidade e a eficácia do teste provo-
cativo da ibopamina com diferentes concentrações em pacien-
tes com glaucoma primário de ângulo aberto. Métodos: Pacien-
tes com glaucoma (mesmo olho) foram aleatoriamente submeti-
dos ao teste provocativo da ibopamina com as duas concentra-
ções comercialmente disponíveis: 1% e 2% com pelo menos 3
semanas de intervalo, mas não superior a 3 meses. Os indiví-
duos normais foram randomizados a uma das concentrações
utilizadas. O teste era considerado positivo se houvesse eleva-
ção da pressão intra-ocular (Pio) superior a 3 ou 4 mmHg 30 ou
45 minutos após o início do teste para se estabelecer a melhor
relação sensibilidade (Se)/especificidade (Es) do teste. Resulta-
dos: Treze pacientes com glaucoma, 15 indivíduos normais com
a ibopamina a 2% e 13 com a ibopamina a 1% foram incluídos.
Não houve diferença estatisticamente significativa em qualquer
uma das médias da Pio entre a ibopamina a 1% ou a 2%. A Pio foi
significativamente maior aos 30 e 45 minutos com ambas as
concentrações (p<0,001). A melhor relação Se/Es foi obtida com
o aumento da Pio >3 mmHg, 45 minutos após o teste com a
ibopamina a 2% (área abaixo da curva ROC: 0,864, Se: 84,6%; Es:
73,3%). Todos os pacientes referiram leve ardência à instilação
da ibopamina. Conclusão: Sugere-se a utilização da ibopamina a
2% como teste provocativo para o glaucoma. Como ambas as
concentrações apresentaram capacidade similar em elevar a Pio,
a Ibopamina a 1% (menor concentração da droga) pode ser
utilizada por períodos prolongados, como na hipotonia ocular.
Descritores: Agonistas dopaminérgicos/administração & do-
sagem; Glaucoma de ângulo aberto/diagnóstico; Pressão intra-
ocular/efeito de drogas; Soluções oftálmicas. Tolerância e efi-
cácia; Sensibilidade e especificidade
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